Todd Foley is a Co-Founder and Chairman of the Board of Directors at Aktis Oncology. Todd is an experienced biotech investor who is currently a Managing Director at MPM Capital and serves on several MPM portfolio company boards alongside Aktis, including CODA Biotherapeutics, Crossbow Therapeutics, Entrada Therapeutics, Iconic Therapeutics, Repare Therapeutics, and Tetherex Pharmaceuticals. He previously served on the board of Semma Therapeutics and guided Selexys Pharmaceuticals to an acquisition by Novartis for $665M in 2016. Todd has managed MPM’s strategic investment relationship with Novartis, which committed $200 million to over a dozen companies in the biotech and healthcare IT space under a variety of creative joint equity/strategic deal structures. Prior to joining MPM in 1999, Todd’s career in the life science industry included business development at Genentech and management consulting with Arthur D. Little. Todd earned his MBA from Harvard Business School and his BS in Chemistry from the Massachusetts Institute of Technology.